Website: https://www.nrgtherapeutics.com/
Develops disease-modifying therapeutics utilizing mitochondrial biology breakthroughs to slow or halt neurodegenerative disorders progression, including Parkinson's and ALS.
VentureRadar Research / Company Website
NRG Therapeutics is applying science in the field of mitochondrial biology to develop disease-modifying therapeutics to slow or halt the progression of neurodegenerative disorders such as Parkinson’s and ALS (also known as motor neurone disease or MND). Its pre-clinical pipeline includes small molecule assets which inhibit the mitochondrial permeability transition pore (mPTP) through a novel mechanism of action.
VentureRadar Research / Company Website
Associated sectors:
Therapeutics; Biotechnology; neuroscience; mitochondrial dysfunction; mitochondrial biology; biotech;
Similar Companies:
Mitobridge
USA
Privately Held
Mitobridge is discovering and developing novel therapeutics that improve mitochondrial functions. Building upon the emerging scientific findings linking mitochondrial dysfunction with disease pathologies, we are progressing innovative approaches to the treatment of diseases with high unmet medical need. Our strategy is to establish proof of concept in rare diseases and then expand into more common diseases. Mitobridge has assembled a strong team with expertise in advancing ground-breaking therapeutics into the clinic. Our scientific founders and advisors include leaders in mitochondrial biology, metabolism and aging with experience in translating novel discoveries into next-generation medicines. We are also using this biology based approach to explore other important pathways with high potential for clinical impact.
MitoRx Therapeutics
United Kingdom
Privately Held
MitoRx aims to become a global developer of medicines arresting the progression of degenerative diseases driven by mitochondrial dysfunction. The company is a preclinical research stage biotechnology company developing their first-in-class, orally delivered, mitochondrial protective therapeutics targeting rare neuromuscular disorders, rare metabolic diseases, and neurodegenerative diseases. MitoRx Therapeutics' proprietary technology exploits an endogenous mechanism which mediates sulfide-signaling, having the effect of substrate replenishment in states of trans-sulfuration deficiency omnipresent in several diseases and certain medical conditions, resulting in the restoration of adaptive metabolism. While sulfide is rapidly metabolised, our products are potent and highly targeted, resulting in small and safe doses.
Mitoimmune Therapeutics
South Korea
Privately Held
MitoImmune Therapeutics Inc. is a drug discovery and development biotech company that harnesses the power of mitochondria and its proprietary technology targeting mitochondria as the source for developing new potential breakthrough therapeutics. Our mission is to increase healthy lifespan by developing treatments for mitochondrial dysfunction-related necrotic and inflammatory diseases.
Celosia Therapeutics
Australia
Privately Held
Celosia Therapeutics is a biotechnology company developing advanced gene therapies to treat neurodegenerative diseases such as ALS, MND, epilepsy, and dementia. Utilizing a proprietary portfolio of patents, the company creates novel disease-modifying therapies like CTx1000, targeting proteins associated with ALS to halt or reverse the progression of these debilitating neurological conditions.
Neuroene Therapeutics LLC
USA
Privately Held
Neuroene Therapeutics is pioneering treatments for neurological diseases by addressing mitochondrial dysfunction, a common trait in conditions like epilepsy, Parkinson’s, and rare mitochondrial disorders. The company has developed innovative, patented VK analogs that are orally bioavailable, well tolerated, and exhibit excellent brain penetration and half-life. These novel compounds target mitochondrial health and energetics, offering new mechanisms of action to meet the critical need for effective neurological disease treatments.
MitoChem Therapeutics
USA
Privately Held
Founded at the Medical University of South Carolina, MitoChem Therapeutics was started by two scientists who saw an opportunity to focus on developing treatments to address the effects of cellular and metabolic dysfunction in neurodegenerative conditions, specifically eye diseases. MitoChem identified a key driver in vision loss and developed a new class of small molecules to treat neurodegeneration by protecting mitochondria.